Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

Platinum derivatives are commonly used for the treatment of patients with metastatic triple-negative breast cancer (TNBC). However, resistance often develops, leading to treatment failure. This expansion cohort (part C2) of the previously reported phase 1b trial (NCT02157792) is based on the recomme...

Descripción completa

Detalles Bibliográficos
Autores principales: Telli, Melinda L., Tolaney, Sara M., Shapiro, Geoffrey I., Middleton, Mark, Lord, Simon R., Arkenau, Hendrik Tobias, Tutt, Andrew, Abramson, Vandana, Dean, Emma, Haddad, Tufia C., Wesolowski, Robert, Ferrer-Playan, Jordi, Goddemeier, Thomas, Grombacher, Thomas, Dong, Jennifer, Fleuranceau-Morel, Patricia, Diaz-Padilla, Ivan, Plummer, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991212/
https://www.ncbi.nlm.nih.gov/pubmed/35393425
http://dx.doi.org/10.1038/s41523-022-00406-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991212/
https://www.ncbi.nlm.nih.gov/pubmed/35393425
http://dx.doi.org/10.1038/s41523-022-00406-0

Ejemplares similares